A Phase III Randomized Study of Oral Sapacitabine In Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
| Principal Investigator: | Sanford Kempin, MD |
| Time frame of study: | Ongoing |
| Location of Study: | Beth Israel Medical Center |
| Contact: | Continuum Cancer Research Program |
Summary:
Previous clinical studies suggest sapacitabine and decitabine are well
suited in providing anti-leukemic activities for the treatment goal of
controlling the disease and improving tumor-related signs/symptoms in
elderly patients suffering from AML.
The primary objective of this study is to compare the overall survival
between those randomized to the group receiving sapacitabine and decitabine,
versus those receiving decitabine alone.
Eligibility and Treatment Plan:
• Age = 70 years
• Diagnosis of acute myeloid leukemia (AML), and for whom the treatment
of choice is low-intensity therapy by investigator assessment or who are
not willing to receive intensive induction therapy recommended by investigator
• Must be able to swallow capsules
Please call for more information.
Copyright © 2008